Interferon signaling in the liver during hepatitis C virus infection

Cytokine

Volumn 59, Issue 3, 2012, Pages 460-466

  Makowska, Zuzanna ^a   Heim, Markus H ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Hepatitis C virus; Interferon; Jak STAT pathway; Liver; USP18

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BOCEPREVIR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON; INTERFERON RECEPTOR; JANUS KINASE; LAMBDA INTERFERON; LAMBDA INTERFERON RECEPTOR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; PROTEINASE INHIBITOR; RIBAVIRIN; STAT1 PROTEIN; STAT2 PROTEIN; TELAPREVIR; UNCLASSIFIED DRUG;

ACUTE DISEASE; CHRONIC DISEASE; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPETENT CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIREMIA; VIRUS ACTIVATION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84865042179     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.015     Document Type: Review

References (97)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl. 1):74-81.
2. Goutagny N., Fatmi A., De Ledinghen V., Penin F., Couzigou P., Inchauspé G., et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003, 187:1951-1958.
3. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
4. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-5025.
5. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wölk B., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
6. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
7. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5:453-463.
8. Egger D., Wölk B., Gosert R., Bianchi L., Blum H.E., Moradpour D., et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002, 76:5974-5984.
9. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003, 77:5487-5492.
10. Barba G., Harper F., Harada T., Kohara M., Goulinet S., Matsuura Y., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997, 94:1200-1205.
11. Boulant S., Targett-Adams P., McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 2007, 88:2204-2213.
12. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007, 9:1089-1097.
13. Targett-Adams P., Hope G., Boulant S., McLauchlan J. Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. J Biol Chem 2008, 283:16850-16859.
14. Targett-Adams P., Boulant S., McLauchlan J. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J Virol 2008, 82:2182-2195.
15. André P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002, 76:6919-6928.
16. Gastaminza P., Kapadia S.B., Chisari F.V. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006, 80:11074-11081.
17. Huang H., Chen Y., Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 2007, 104:18666-18670.
18. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
19. Major M.E., Mihalik K., Fernandez J., Seidman J., Kleiner D., Kolykhalov A.A., et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999, 73:3317-3325.
20. Grüner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000, 181:1528-1536.
21. Pape G.R., Gerlach T.J., Diepolder H.M., Grüner N., Jung M., Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepatitis 1999, 6(Suppl. 1):36-40.
22. Watanabe H., Saito T., Shinzawa H., Okumoto K., Hattori E., Adachi T., et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol 2003, 71:56-61.
23. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305.
24. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
25. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34:809-816.
26. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
27. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
28. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol 2000, 74:2046-2051.
29. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
30. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
31. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32.
32. Yoneyama M., Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem 2007, 282:15315-15318.
33. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
34. Croll A.D., Wilkinson M.F., Morris A.G. Gamma-interferon production by human low-density lymphocytes induced by T-cell mitogens. Immunology 1986, 58:641-646.
35. Handa K., Suzuki R., Matsui H., Shimizu Y., Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2) II IL 2-induced interferon gamma production. J Immunol 1983, 130:988-992.
36. Kurane I., Innis B.L., Nisalak A., Hoke C., Nimmannitya S., Meager A., et al. Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest 1989, 83:506-513.
37. Bach E.A., Aguet M., Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997, 15:563-591.
38. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
39. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4.
40. Decker T., Lew D.J., Mirkovitch J., Darnell J.E. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO J 1991, 10:927-932.
41. Strehlow I., Decker T. Transcriptional induction of IFN-gamma-responsive genes is modulated by DNA surrounding the interferon stimulation response element. Nucleic Acids Res 1992, 20:3865-3872.
42. Decker T., Lew D.J., Darnell J.E. Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylate-binding protein gene. Mol Cell Biol 1991, 11:5147-5153.
43. Pine R., Canova A., Schindler C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J 1994, 13:158-167.
44. Kessler D.S., Veals S.A., Fu X.Y., Levy D.E. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 1990, 4:1753-1765.
45. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., Macdonald M.R., et al. Interferons α and λ Inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
46. Der S.D., Zhou A., Williams B.R.G., Silverman R.H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Nat Acad Sci USA 1998, 95:15623-15628.
47. Lanford R.E., Guerra B., Lee H., Chavez D., Brasky K.M., Bigger C.B. Genomic response to interferon-α in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006, 43:961-972.
48. Sarasin-Filipowicz M., Wang X., Yan M., Duong F.H.T., Poli V., Hilton D.J., et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009, 29:4841-4851.
49. Larner A.C., Chaudhuri A., Darnell J.E. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem 1986, 261:453-459.
50. Friedman R.L., Manly S.P., McMahon M., Kerr I.M., Stark G.R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984, 38:745-755.
51. Fenner J.E., Starr R., Cornish A.L., Zhang J.-G., Metcalf D., Schreiber R.D., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006, 7:33-39.
52. Malakhova O.A., Kim K.I., Luo J.-K., Zou W., Kumar K.S., Fuchs S.Y., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006, 25:2358-2367.
53. Zimmerer J.M., Lesinski G.B., Kondadasula S.V., Karpa V.I., Lehman A., RayChaudhury A., et al. IFN-α-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 2007, 178:4832-4845.
54. Makowska Z., Duong F.H.T., Trincucci G., Tough D.F., Heim M.H. Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology 2011, 53:1171-1180.
55. François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS ONE 2011;6:e22200.
56. Jaks E., Gavutis M., Uzé G., Martal J., Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007, 366:525-539.
57. Chen L., Borozan I., Feld J., Sun J., Tannis L.-L., Coltescu C., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437-1444.
58. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H.T., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008, 105:7034-7039.
59. Asselah T., Bieche I., Narguet S., Sabbagh A., Laurendeau I., Ripault M.-P., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008, 57:516-524.
60. Garaigorta U., Chisari F.V. Hepatitis C virus blocks interferon effector function by inducing protein kinase r phosphorylation. Cell Host Microbe 2009, 6:513-522.
61. Chang M., Williams O., Mittler J., Quintanilla A., Carithers R.L., Perkins J., et al. Dynamics of hepatitis C virus replication in human liver. Am J Pathol 2003, 163:433-444.
62. Liang Y., Shilagard T., Xiao S.-Y., Snyder N., Lau D., Cicalese L., et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009, 137:1448-1458.
63. Pal S., Shuhart M.C., Thomassen L., Emerson S.S., Su T., Feuerborn N., et al. Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J Virol 2006, 80:2280-2290.
64. Heim M.H., Moradpour D., Blum H.E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999, 73:8469-8475.
65. Duong F.H.T., Filipowicz M., Tripodi M., La Monica N., Heim M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004, 126:263-277.
66. Christen V., Treves S., Duong F.H.T., Heim M.H. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007, 46:558-565.
67. Takahashi K., Asabe S., Wieland S., Garaigorta U., Gastaminza P., Isogawa M., et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci 2010.
68. M.T. Dill, Z. Makowska, F.H.T. Duong, F. Merkofer, M. Filipowicz, T.F. Baumert, L. Tornillo, L. Terracciano, M.H. Heim, Interferon-γ Stimulated Genes, but not USP18, are Expressed in Livers of Patients with Acute Hepatitis C, Gastroenterology, (2012).
69. Saito T., Owen D.M., Jiang F., Marcotrigiano J., Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008, 454:523-527.
70. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
71. Seth R.B., Sun L., Ea C.-K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
72. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6:981-988.
73. Xu L.-G., Wang Y.-Y., Han K.-J., Li L.-Y., Zhai Z., Shu H.-B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005, 19:727-740.
74. Bellecave P., Sarasin-Filipowicz M., Donzé O., Kennel A., Gouttenoire J., Meylan E., et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010, 51:1127-1136.
75. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
76. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002, 169:6668-6672.
77. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C.M., Ikeda M., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005, 102:2992-2997.
78. Yang D., Liu N., Zuo C., Lei S., Wu X., Zhou F., et al. Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS ONE 2011, 6:e27552.
79. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. [1345.e1-7].
80. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
81. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
82. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
83. Marukian S., Andrus L., Sheahan T.P., Jones C.T., Charles E.D., Ploss A., et al. Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 2011, 54:1913-1923.
84. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004, 78:13779-13792.
85. Jouan L., Chatel-Chaix L., Melançon P., Rodrigue-Gervais I.-G., Raymond V.-A., Selliah S., et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. J Hepatol 2012, 56:70-77.
86. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001, 75:7059-7066.
87. Su A.I., Pezacki J.P., Wodicka L., Brideau A.D., Supekova L., Thimme R., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Nat Acad Sci USA 2002, 99:15669-15674.
88. Major M.E., Dahari H., Mihalik K., Puig M., Rice C.M., Neumann A.U., et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004, 39:1709-1720.
89. Nanda S., Havert M.B., Calderón G.M., Thomson M., Jacobson C., Kastner D., et al. Hepatic transcriptome analysis of hepatitis c virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008, 3:e3442.
90. Yu C., Boon D., McDonald S.L., Myers T.G., Tomioka K., Nguyen H., et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol 2010, 84:11264-11278.
91. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457.
92. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.-C., Ulsenheimer A., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
93. Randall G., Chen L., Panis M., Fischer A.K., Lindenbach B.D., Sun J., et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006, 131:1584-1591.
94. Pawlotsky J. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
95. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112S-121S.
96. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-244.
97. Zeuzem S. Emerge study group, pegylated interferon-lambda (pegIFN-lambda) shows superior viral response with improved safety and tolerability versus pegIFN-(alpha)-2a in HCV patients (G1/2/3/4): EMERGE phase IIb through week 2011;12.